Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials

Endocrine journal

article

Tao Long¹  Jin-ting Lin²  Min-hua Lin²  Qian-long Wu²  Jian-mei Lai²  Sheng-zhen Li²  Zi-chao Zhou²  Ji-yuan Zeng²  Jia-shuan Huang²  Chun-ping Zeng¹  Yao-ming Lai³ 

[1] Department of Endocrinology, The Fifth Affiliated Hospital of Guangzhou Medical University;Department of Pediatrics, Pediatrics School, Guangzhou Medical University;Department of Rehabilitation Medicine, The Fifth Affiliated Hospital of Guangzhou Medical University

关键词: Insulin degludec/aspart;    Insulin glargine;    Type 2 diabetes;    Meta-analysis;   

DOI  :  10.1507/endocrj.EJ21-0692

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

Recent studies have found compared with insulin glargine (IGlar), insulin degludec/aspart (IDeg/Asp) may provide adequate glycemic control and prevent hypoglycemia events in type 2 diabetes mellitus (T2DM). Consequently, we performed a meta-analysis to appraise and compare the efficiency and safety of IDeg/Asp and IGlar in the treatment of T2DM. We sought the databases including PubMed, Embase, Scopus, Cochrane library to confirm related articles which inspected the effect of IDeg/Asp versus IGlar for the treatment of T2DM until May 2021. Finally, six randomized controlled trials (RCTs) of 1,346 patients were included. The results showed that IDeg/Asp significantly decreased the mean hemoglobin A1c (HbA1c) level but was prone to serious adverse events, and IGlar increased the nocturnal confirmed hypoglycemia events. Besides, there were no significant changes in other indicators, including mean fasting plasma glucose (FPG) level, nine-point self-measured plasma glucose (SMPG) level, and adverse events. What’s more, we found that there was no significant difference in the occurrence of hypoglycemia overall, but our subgroup analysis of confirmed hypoglycemia revealed the population in this subgroup (duration of diabetes ≤11 years) might has its particularity effecting the hypoglycemia outcome. Concerning efficiency, IDeg/Asp may have advantages in controlling the mean HbA1c level. Regarding safety, IGlar might increase the risk of nocturnal confirmed hypoglycemia. Further evidence is needed to compare better the efficiency and safety of IDeg/Asp versus IGlar therapy.

【 授权许可】

Unknown